515 related articles for article (PubMed ID: 1700746)
21. Human lymphokine-activated killer cells are cytotoxic against cells infected with Toxoplasma gondii.
Subauste CS; Dawson L; Remington JS
J Exp Med; 1992 Dec; 176(6):1511-9. PubMed ID: 1460415
[TBL] [Abstract][Full Text] [Related]
22. Comparative studies of CD3- and CD3+ CD56+ cells: examination of morphology, functions, T cell receptor rearrangement, and pore-forming protein expression.
Ortaldo JR; Winkler-Pickett RT; Yagita H; Young HA
Cell Immunol; 1991 Sep; 136(2):486-95. PubMed ID: 1714795
[TBL] [Abstract][Full Text] [Related]
23. Lysis of tumor cells by CD3+4-8-16+ T cell receptor alpha beta- clones, regulated via CD3 and CD16 activation sites, recombinant interleukin 2, and interferon beta 1.
van de Griend RJ; Tax WJ; van Krimpen BA; Vreugdenhil RJ; Ronteltap CP; Bolhuis RL
J Immunol; 1987 Mar; 138(5):1627-33. PubMed ID: 2949018
[TBL] [Abstract][Full Text] [Related]
24. In vitro proliferation and cloning of CD3- CD16+ cells from human thymocyte precursors.
Mingari MC; Poggi A; Biassoni R; Bellomo R; Ciccone E; Pella N; Morelli L; Verdiani S; Moretta A; Moretta L
J Exp Med; 1991 Jul; 174(1):21-6. PubMed ID: 1711562
[TBL] [Abstract][Full Text] [Related]
25. Development of four donor-specific phenotypes in human long-term lymphokine-activated killer cell cultures.
Vollenweider I; Moser R; Groscurth P
Cancer Immunol Immunother; 1994 Nov; 39(5):305-12. PubMed ID: 7987862
[TBL] [Abstract][Full Text] [Related]
26. Activation via the CD3 and CD16 pathway mediates interleukin-2-dependent autocrine proliferation of granular lymphocytes in patients with granular lymphocyte proliferative disorders.
Hoshino S; Oshimi K; Teramura M; Mizoguchi H
Blood; 1991 Dec; 78(12):3232-40. PubMed ID: 1835892
[TBL] [Abstract][Full Text] [Related]
27. Augmented human-tumor-cytolytic activity of peripheral blood lymphocytes and cells from a mixed lymphocyte/tumor culture activated by interleukin-12 plus interleukin-2, and the phenotypic characterization of the cells in patients with advanced carcinoma.
Koyama S
J Cancer Res Clin Oncol; 1997; 123(9):478-84. PubMed ID: 9341896
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-2-activated murine cell lines with macrophage- and B-lymphoblast-lytic activity.
Suzuki H; Ikemoto M; Yokoyama A; Kamitani T; Yamashita N; Maruyama M; Yano S
Cell Immunol; 1991 Jan; 132(1):127-39. PubMed ID: 1829651
[TBL] [Abstract][Full Text] [Related]
29. A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytes.
Shau H; Isacescu V; Ibayashi Y; Tokuda Y; Golub SH; Fahey JL; Sarna GP
J Biol Response Mod; 1990 Feb; 9(1):71-80. PubMed ID: 2319261
[TBL] [Abstract][Full Text] [Related]
30. Human pulmonary natural killer (NK) cells exhibit limited lymphokine-activated killer (LAK) activity.
Yarbrough WC; Weissler JC
Am J Respir Cell Mol Biol; 1989 Oct; 1(4):305-11. PubMed ID: 2483121
[TBL] [Abstract][Full Text] [Related]
31. Adhesion molecules on MHC-nonrestricted lymphocytes: high density expression and role in oncolysis.
Savary CA; Lotzová E
Lymphokine Cytokine Res; 1992 Jun; 11(3):149-56. PubMed ID: 1391234
[TBL] [Abstract][Full Text] [Related]
32. Morphological, phenotypic and functional characteristics of a pure population of CD56+ CD16- CD3- large granular lymphocytes generated from human duodenal mucosa.
Pang G; Buret A; Batey RT; Chen QY; Couch L; Cripps A; Clancy R
Immunology; 1993 Jul; 79(3):498-505. PubMed ID: 7691728
[TBL] [Abstract][Full Text] [Related]
33. Distinct granzyme expression in human CD3- CD56+ large granular- and CD3- CD56+ small high density-lymphocytes displaying non-MHC-restricted cytolytic activity.
Smyth MJ; Browne KA; Kinnear BF; Trapani JA; Warren HS
J Leukoc Biol; 1995 Jan; 57(1):88-93. PubMed ID: 7530284
[TBL] [Abstract][Full Text] [Related]
34. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
Tilden AB; Itoh K; Balch CM
J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627
[TBL] [Abstract][Full Text] [Related]
35. The role of lymphotoxin in the IL-2-driven differentiation of human lymphokine-activated T-killer (T-LAK) cells in vitro.
Abe Y; Van Eden M; Gatanaga M; Wang FI; Brightbill HD; Granger GA; Gatanaga T
Lymphokine Cytokine Res; 1993 Oct; 12(5):279-83. PubMed ID: 8260536
[TBL] [Abstract][Full Text] [Related]
36. Cytological characteristics of human glioma-infiltrating lymphocytes stimulated with recombinant interleukin 2 and an anti-CD3 antibody.
Kikuchi T; Watanabe M; Ohno T
Jpn J Cancer Res; 1991 Mar; 82(3):339-45. PubMed ID: 1827092
[TBL] [Abstract][Full Text] [Related]
37. CD8+CD11b+ peripheral blood T lymphocytes contain lymphokine-activated killer cell precursors.
Dianzani U; Zarcone D; Pistoia V; Grossi CE; Pileri A; Massaia M; Ferrarini M
Eur J Immunol; 1989 Jun; 19(6):1037-44. PubMed ID: 2502419
[TBL] [Abstract][Full Text] [Related]
38. Induction of lymphokine-activated killer cells with low-dose interleukin 2 and interferon-gamma in oral cancer patients.
Yoneda K; Yamamoto T; Ueta E; Osaki T
J Clin Immunol; 1992 Jul; 12(4):289-99. PubMed ID: 1512302
[TBL] [Abstract][Full Text] [Related]
39. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
[TBL] [Abstract][Full Text] [Related]
40. Highly oncolytic adherent lymphocytes: therapeutic relevance for leukemia.
Lotzová E; Savary CA; Totpal K; Schachner J; Lichtiger B; McCredie KB; Freireich EJ
Leuk Res; 1991; 15(4):245-54. PubMed ID: 2030606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
